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ABSTRACT                        Serotonin is probably unique among the monoamines in that its effects are
subserved by as many as 13 distinct heptahelical, G protein-coupled receptors (GPCRs) and a
ligand-gated ion channel family (5-HT3).  These receptors are divided into seven distinct classes
(5-HT1 to 5-HT7) largely on the basis of their structural, transductional and operational char-
acteristics. While this degree of physical diversity clearly underscores the physiological
importance of serotonin, evidence for an even greater degree of operational diversity
continues to emerge. Here, we will review this diversity and its physiological and possibly
pathophysiological consequences. Indeed, 5-HT research which is about 50 years old, has
resulted in  numerous therapeutic agents, some of which have a major impact on disease man-
agement. Thus,  selective 5-HT reuptake inhibitors (SSRIs) are among the most widely used
drugs in  depression and other disorders such as anxiety, social phobia, panic disorders, or
obsessive compulsive disorders (OCDs) to name a few. The discovery of 5-HT1B/1D receptor
agonists (the triptans) for treating migraine,  5-HT3 receptor antagonists for chemotherapy and
radiation-induced emesis, and finally the emergence of 5-HT3 / 5-HT4 ligands to treat irritable
bowel syndrome (IBS), all represent major advances in the field. Finally, the role of 5-HT in the
mechanism of action of antipsychotic agents still is a topic of intense research, which promises
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Serotonin (5-hydroxytryptamine; 5-HT) produces its effects
through a variety of membrane-bound receptors both in the
central and peripheral nervous system (CNS/PNS) as well as
in a number of non-neuronal tissues (e.g. gut, cardiovascular
system and blood). The main source of 5-HT is in the gut,
more precisely enterochromaffin cells, where it is synthesised
from tryptophan. It can be released into the gut lumen e.g.
as a reaction to pressure and act on receptors located on the
smooth muscle, or into the portal blood circulation, by a
variety of nervous or alimentary stimuli. 5-HT is also found
in enteric neurones. In the blood, the vast majority of 5-HT
is not free, but to be found in the platelets, which are endowed
with a very active uptake system (they do probably not
synthesise 5-HT) and 5-HT is stored in storage granules.
Large amounts of 5-HT are released during platelet aggre-
gation, and it can act locally on endothelial cells and vascular
smooth muscle. 5-HT is also found in mast cells. In the
central and peripheral nervous system, 5-HT acts as a
neurotransmitter on a large variety of receptors, which may
be located pre or post synaptically. 5-HT is also found in the
pineal gland, where it is believed to serve essentially as a
precursor for the synthesis of melatonin by 5-HT-N-acetyl-
transferase and hydroxyindole-O-methyltransferase, under
the control of the clock in the suprachiasmatic nucleus which
during the circadian rhythm modulates enzyme activity levels
up to 50 fold.
The serotoninergic system is one of the oldest neurotrans-
mitter/hormone systems in evolution, which may explain
why 5-HT interacts with such a diversity of receptors of the
G protein coupled family and the ligand gated family,
similarly to acetylcholine, GABA or glutamate. 5-HT was
discovered in the gut in the 1930s and called enteramine, then
rediscovered in the 1940s in the blood and called serotonin,
as it had vasoconstrictor features. 5-HT is synthesised from
L-tryptophan, the tryptophan hydroxylase forming 5-hydrox-
ytrytophan (5-HTP), which by the L amino acid decar-
boxylase leads to 5-HT; serotonin can be conjugated with
glucuronide or sulfate or in nerves metabolised via mono-
amine oxydase to 5-hydroxyindolacetaldehyde and finally to
5-hydroxyindolacetic acid (via aldehydedehydrogenase). It
can also lead to 5-hydroxytryptophol by an aldehyde-
reductase in some peripheral nerves. Thus, 5-HT acts both
as a neurotransmitter with all the features, such as intra-
cellular storage, activity dependent release, the existence of
both pre- and postsynaptic receptors, an active uptake system,
via the serotonin transporter and metabolising/inactivating
enzymes and a hormone, released into the blood or gut to
work more distantly.
With the exception of 5-HT3 receptors (ligand-gated ion
channels), 5-HT receptors belong to the G protein-coupled
receptor (GPCR) superfamily and, with at least fourteen
distinct members, represents one of the most complex
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families of neurotransmitter receptors. Multiple splice
variants (5-HT4, 5-HT7) or RNA edited isoforms (5-HT2C)
have been described; there is also evidence that homo- and
heterodimerisation (5-HT1B/1D) can occur. Furthermore,
peptide or lipid modulators of 5-HT receptors have been
described such as 5-HT moduline (Leu-Ser-Ala-Leu (LSAL),
a putative product of a chromogranin), which has selectivity
for the 5-HT1B and 5-HT1D receptors, or oleamide, which acts
on several receptors (e.g. 5-HT2A/2C and 5-HT7).
The 5-HT receptor family has been a target of intense
research, in both academia and the pharmaceutical industry,
with the identification of more potent and selective ligands
for the different receptor subtypes as a major goal. Such
selective receptor probes should help to better define the
function(s) of these receptors, and lead to drug treatments
with fewer side effects. Molecular genetics offer another
approach for studying distinct 5-HT receptor subtypes via the
generation of gene-targeted and transgenic lines of mice with
altered expression of 5-HT receptor or transporter genes. 5-
HT is also a substrate for the 5-HT transporter, itself an
important target in the treatment of depression and social
phobia. It is the target for selective serotonin reuptake
inhibitors (SSRIs) such as fluoxetine, paroxetine and cita-
lopram. Thus, 5-HT has been implicated in the aetiology of
numerous disease states, including depression, anxiety, social
phobia, schizophrenia, obsessive-compulsive, panic-dis-
orders, migraine, hypertension, pulmonary hypertension,
eating disorders, vomiting and irritable bowel syndrome
(IBS).
Current criteria for classifying 5-HT receptors
The classification of 5-HT receptors began in 1957, when it
was found that 5-HT effects in the guinea pig ileum could be
blocked in part by morphine (M), and in part by dibenzyline
(D). Gaddum and Picarelli proposed a subdivision into 5-HT
M and 5-HT D receptors (Gaddum and Picarelli 1957).
However, neither morphine nor dibenzyline are selective. In
1976 utilising radioligand-binding, the presence of 5-HT
receptors was postulated in brain. Then in 1979, Peroutka and
Snyder demonstrated the presence of two distinct 5-HT
receptor binding sites, using [3H]5-HT, [3H]spiperone, and
[3H]LSD. These sites were named 5-HT1 and 5-HT2. The M
receptor was distinct from the 5-HT1 and 5-HT2 receptors in
both function and distribution, whereas the D receptor
corresponded pharmacologically to the 5-HT2 binding site.
As a result, Bradley and colleagues (1986) proposed the
existence of three groups of 5-HT receptors, named 5-HT1-
like, 5-HT2 and 5-HT3, the latter corresponding to the M
Receptor subtypes represented by shaded boxes and lower case designate receptors that have not been demonstrated to
definitively function in native systems.  Abbreviations: 3’-5’ cyclic adenosine monophosphate (cAMP); phospholipase C
(PLC); negative (-ve); positive (+ve).
Figure 1. Graphical representation of the current classification of 5-hydroxytryptamine (5-HT) receptors.
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receptor. The scheme, based primarily on functional criteria,
represented a useful classification framework, but with the
widespread use of radioligands and second messenger
systems in the mid 1980’s, subtypes of 5-HT1 receptor
binding sites were described; and it became rapidly obvious
that the 5-HT1C receptor would be better classified within the
5-HT2 family, suggesting 5-HT2 subtypes also. A novel 5-HT
receptor was identified in the gastrointestinal (G. I.) tract and
brain, termed 5-HT4. In 1988 then, the molecular biology era
started with the cloning of the 5-HT1A receptor. Soon, most
known or suspected 5-HT receptors were cloned in close
succession. This work led to the identification of a number
of ‘new’ receptors, without obvious physiological counter-
parts. Tentatively termed 5-ht1E, 5-ht1F, 5-ht5A, 5-ht5B, 5-ht6, 5-
HT7, they required integration into the classification. Thus,
the Serotonin Club Receptor Nomenclature Committee
proposed a new classification system based on operational,
structural and transductional information (Humphrey et al.
1993). These principles were subsequently applied to addi-
tional receptor families by the receptor Nomenclature
Committee of the International Union of Pharmacology (NC-
IUPHAR). The current classification (Hoyer et al. 1994) is
progressively adapted to incorporate new information,
obtained with both recombinant and native receptors, and
favours an alignment of nomenclature with the human
genome to avoid species differences (see Hartig et al. 1996;
Hoyer and Martin 1997). Currently, seven families of 5-HT
receptors have been recognised. A graphical representation
of the current classification of 5-HT receptors is given in
Figure 1.
5-HT1 receptors
The 5-HT1 receptor class comprises five receptors (5-HT1A,
5-HT1B, 5-HT1D, 5-ht1E and 5-ht1F) which, in humans, share
40-63 % overall sequence identity and couple somewhat
preferentially to Gi/o to inhibit cAMP formation (see Tables
1 and 2). The 5-ht1E and 5-ht1F receptors are given a lower
case appellation to denote that endogenous receptors with a
physiological role have not yet been found. In contrast, 5-
HT1A, 5-HT1B and 5-HT1D receptors have been demonstrated
functionally in a variety of tissues. The 5-HT1C designation
is vacant, as the receptor was renamed 5-HT2C, due to struc-
tural, operational and transductional similarities with the 5-




The human 5-HT1A receptor is located on chromosome
5q11.2-q13. 5-HT1A receptors are largely distributed through-
out the CNS. In the raphé nuclei, they are somatodendritic
and act as autoreceptors to inhibit cell firing; postsynaptic 5-
HT1A receptors are present in limbic structures, particularly
the hippocampus. 5-HT1A receptors mediate neuronal hyper-
polarisation, via G-protein coupled K+ channels. In the G.I.
tract, 5-HT1A receptors on the guinea pig myenteric plexus
act as inhibitory modulators of fast excitatory postsynaptic
potentials.
5-HT1A receptors have been implicated in the neuro-
endocrine regulation of adrenocorticotrophic hormone
(ACTH) secretion. Activation of postsynaptic 5-HT1A recep-
tors induces a behavioural syndrome: flat body posture,
reciprocal forepaw treading and head weaving. The sponta-











Previous names - 5-HT
1Dβ 5-HT1Dα - 5-ht1Eβ, 5-HT6
Selective agonists 8-OH-DPAT Sumatriptan Sumatriptan - LY 334370
L 694247 PNU 109291
Selective antagonists (pK
B
) (±)WAY 100635 (8.7) GR 55562 (7.4) BRL 15572 (7.9) - -
SB 224289 (8.5)
SB 236057 (8.9)
Radioligands [3H]WAY100635 [125I]GTI [125I]GTI [3H]5-HT [125I]LSD
[3H]8-OH-DPAT [125I]CYP (rodent) [3H]Sumatriptan [3H]LY 334370
[3H]Sumatriptan [3H]GR 125743
[3H]GR 125743










Gene/Chromosomal HTR1A/5q11.2-q13 HTR1B/6q13 HTR1D/1p34.3-36.3 HTR1E/6q14-15 HTR1F/3p11-p14.1
   localisation
Structural information h421 P8908 h390 P28222 h377 P28221 h365 P28566 h366 P30939
m421 Q64264 m386 P28334 m374 Q61224 m366 Q02284
r422 P19327 r386 P28564 r374 P28565 r366 P30940
†5-HT1B and 5-HT1D receptor nomenclature has been revised (Hartig et al. 1996); only the non-rodent form of the receptor was previously called 5-HT1Dβ.  
$Displays
a different pharmacology to the rodent form of the receptor.
4
Hannon, Hoyer
neous tail-flick response has also been attributed to post-
synaptic 5-HT1A receptor activation, whereas evidence for a
presynaptic 5-HT1A (auto)receptor in the hyperphagic re-
sponse appears convincing. The hypothermic response to 5-
HT1A agonists in the rat implies both pre- and postsynaptic
mechanisms. A decrease in blood pressure and heart rate, and
increased locomotor responses can be induced by central 5-
HT1A receptor activation. The proposed role of 5-HT1A
receptors in modulating anxiety-related behaviours is sup-
ported by recent studies utilising 5-HT1A receptor knock-out
(KO) mice. They display increased anxiety in a number of
tests (e.g. elevated plus maze, elevated zero maze, open
field). Moreover, they show decreased baseline immobility
in the forced swim and tail suspension tests.
5-HT1A receptor agonists, such as buspirone or gepirone,
are being used/developed for the treatment of anxiety and
depression. Furthermore, the 5HT1A receptor and beta adren-
oceptor antagonist, pindolol, was reported to enhance the
therapeutic efficacy, and shorten the onset of action of SSRIs,
upon co-administration in severely depressed patients.
However, both positive and negative findings have been
reported, as is common in depression trials. Flesinoxan, a 5-
HT1A receptor agonist, was initially developed as an anti-
hypertensive agent, however its effects in patients were
disappointing and this approach has now been abandoned.
Several agonists show selectivity for the 5-HT1A receptor,
particularly 8-hydroxy-di-n-propylamino tetralin (8-OH-
DPAT), a full agonist in most systems, whilst the anxiolytics,
buspirone and gepirone, and other ligands such as MDL
72832 are partial agonists. To date, the only selective high
affinity silent antagonist at this receptor is WAY 100635. The
agonists U-92016A and (+)UH 301 and the antagonists, (-)




The 5-HT1B and 5-HT1D receptors have experienced a com-
plex and debated history. The 5-HT1B receptor was originally
defined according to operational criteria (high affinity for
some indole blockers) and was thought to be a rodent specific
receptor, whereas the 5-HT1D receptor was found in other
species (similar distribution and function, but different
“pharmacology”). It turned out that in all species investi-
gated, two related receptors could be cloned (5-HT1B and 5-
HT1D). The differences in the pharmacology of the 5-HT1B
receptor across species are attributable to the mutation of a
single amino acid Asp123 to Arg123. The human 5-HT1B recep-
tor is located on chromosome 6q13.
5-HT1B receptors are expressed in the CNS, in the basal
ganglia, striatum and frontal cortex and are thought to serve
as terminal autoreceptors. The receptor may also act as a
terminal heteroreceptor controlling the release of other
neurotransmitters, such as acetylcholine, glutamate,
dopamine, noradrenaline and γ-aminobutyric acid. Additional
effects tentatively attributed in rats to central 5-HT1B receptor
activation, include hyperlocomotion, hypophagia, hypo-
thermia and penile erection. The receptors are also found on
cerebral arteries and other vascular tissues. 5-HT1B receptors
mediate contraction of rat caudal arteries. Other 5-HT1B
effects include inhibition of noradrenaline release in vena
cava and inhibition of plasma extravasation produced by
trigeminal ganglion stimulation in guinea pigs and rats.
Interest in 5-HT1B receptor agonists has been triggered by
the anti-migraine properties of sumatriptan, a non-selective
5-HT1D/1B receptor agonist; various agonists have been
developed for this indication (dihydroergotamine (DHE),
zolmitriptan, naratriptan, rizatriptan, elitriptan, almotriptan,
donitriptan and others). The putative 5HT1B receptor agonist,
anpirtoline, has analgesic and antidepressant-like properties
in rodents and interestingly 5-HT1B receptor KO mice were
reported to be highly aggressive and show an increased
preference for alcohol. In contrast to the 5-HT1A receptor KO
mouse, the 5-HT1B receptor KO has a different, and in most
cases opposite behavioural profile, displaying decreases in
measures of anxiety in the elevated plus maze, open field and
tail suspension tests, in addition to an increase in aggression
in the resident intruder paradigm. However, the development
of 5-HT1B agonist ‘serenics’ such as eltoprazine was not
successful; the expected anti-aggressive effects were not
observed in patients.
Selective 5-HT1B agonists include MK 462 (rizatriptan),
BW 311C90 (zolmitriptan), SKF 99101H, GR 46611, L
694247, and CP 93129 (in rodents). However, some of them,
e.g. sumatriptan or LY 334370 have significant affinity to 5-
ht1F receptors. Clearly, some of these molecules will recog-
nise 5-HT1B and 5-HT1D receptors almost equally, e.g. L
694247. However, SB 216641 (h5-HT1B) and BRL 15572
(h5-HT1D) have permitted discrimination of the effects
mediated by one or the other of these receptors, in appro-
priate species, at the level of presynaptic auto- and heterore-
ceptors. Of 5-HT1B receptor antagonists, the most commonly
used (in rodents), pindolol, cyanopindolol and SDZ 21009
are equipotent at the 5-HT1A receptor, where they have
antagonist or partial agonist properties, (and are potent beta-
adrenoceptor antagonists). SB 216641, SB 272183 and GR
55562 demonstrate a certain degree of 5-HT1B selectivity. SB
224289 and SB 236057 are inverse agonists, allowing the
characterisation of 5-HT1B receptor tone. These new com-
pounds confirm that terminal 5-HT autoreceptors are of the
5-HT1B type.
Radiolabelled ligands include [3H]-GR 125743, a 5-HT1D/
1B receptor antagonist, [125I]5-hydroxytryptamine-5-O-
carboxymethylglycyltyrosinamide (GTI) or [3H]alniditan.
Finally, in rodents, [125I]cyanopindolol under appropriate
conditions labels 5-HT1B sites.
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The 5-HT1D receptor is located on chromosome 1p34.3-p36.3
and possesses 63 % overall structural homology with the 5-
HT1B receptor. Its level of expression is very low compared
with 5-HT1B receptors and it has been difficult to assign a
functional role. The characteristics of the 5-HT1B and 5-HT1D
subtypes are now well established, and the use of the new 5-
HT1B/1D selective ligands, SB 216641 (h5-HT1B) and BRL
15572 (h5-HT1D), suggests the presence of a 5-HT1D auto-
receptor in the dorsal raphé nuclei. 5-HT1D receptors in
human heart modulate 5-HT release. The currently available
anti-migraine drugs do not distinguish between 5-HT1B and
5-HT1D receptors. However, the selective 5-HT1D receptor
agonist, PNU 109291, has been shown to play a significant
role in the suppression of meningeal neurogenic inflam-
mation and trigeminal nociception in guinea pig, suggesting
the 5-HT1D receptor related headaches, but such drugs are
devoid of vascular activity confirming that it is the 5-HT1B
receptor that mediates the vasoconstrictor effects produced
by sumatriptan and analogues. Both 5-HT1B and 5-HT1D
receptor immunoreactivity is found in human trigeminal
ganglia, where the receptors colocalise with calcitonin gene-




The putative 5-ht1E receptor was identified in binding studies
in human frontal cortex, but its overall distribution is still to
be described due to the absence of adequate tools. It is a 365
amino acid protein negatively linked to adenylyl cyclase in
recombinant cell systems, present on human chromosome
6q14-q15. 5-ht1E receptor mRNA and recognition sites
exhibiting the pharmacological characteristics of the receptor
have been mapped in rodent and human brain. However,
confirmation of a true physiological role for 5-ht1E receptors
is still lacking; hence, they retain their lower case appellation.
A thorough characterisation of the 5-ht1E receptor awaits the




The 5-ht1F receptor located on chromosome 3p11, has 366
amino acids, is negatively linked to adenylyl cyclase in
recombinant cell systems, and most closely related to the 5-
ht1E receptor with > 70 % sequence homology across the
seven transmembrane domains. Little is known about the
distribution and function of the 5-ht1F receptor; mRNA for the
human receptor protein has been identified in the brain
(dorsal raphé, hippocampus, cortex, striatum, thalamus and
hypothalamus), mesentery and uterus. The anti-migraine 5-
HT1B/1D agonist sumatriptan labels 5-ht1F sites with high
affinity. The binding site distribution obtained was very
similar to that for 5-ht1F mRNA. Naratriptan also has affinity
for 5-ht1F receptors and it has been hypothesised that they
might be a target for anti-migraine drugs. 5-ht1F receptor
mRNA has been detected in the trigeminal ganglia, stim-
ulation of which leads to plasma extravasation in the dura, a
component of neurogenic inflammation thought to be a
possible cause of migraine. LY 334370, a selective 5-ht1F
receptor agonist, inhibits trigeminal stimulation-induced
early activated gene expression in nociceptive neurones in the
rat brainstem. LY 334370, as a radioligand, shows prominent
binding in the cortical areas, striatum, hippocampus and
olfactory bulb compatible with 5-ht1F mRNA distribution.
5-ht1F selective ligands i.e. LY 344864 and BRL 54443,
are currently in development (migraine), however they also
have affinity for 5-ht1E receptors.
5-HT2 receptors
5-HT2A, 5-HT2B and 5-HT2C receptors exhibit 46-50 % overall
sequence identity and couple preferentially to Gq/11 to in-
crease inositol phosphates and cytosolic [Ca++] (see Tables
1 and 3). The 5-HT2A receptor refers to the classical D
receptor initially described by Gaddum and Picarelli (1957),
and later defined as the 5-HT2 receptor by Peroutka and
Snyder (1979). 5-HT2B receptors mediate the contractile
action of 5-HT in the rat fundus. In human pulmonary artery
endothelial cells, 5-HT2B receptor stimulation causes intracel-
lular calcium release. The third 5-HT2 subtype corresponds
to the previously known 5-HT1C receptor, which was re-




The 5-HT2A receptor located on human chromosome 13q14-
q21, has 471 amino acids in rat, mouse and humans. It is
widely distributed in peripheral and central tissues. 5-HT2A
receptors mediate contractile responses in many vascular and
non-vascular smooth muscle preparations, e.g. bronchial,
uterine, ileal and urinary smooth muscle. 5-HT2A receptors
mediate platelet aggregation and increased capillary. Central-
ly, these receptors are principally located in the cortex,
claustrum and basal ganglia. 5-HT2A receptor activation
stimulates hormone secretion e.g. ACTH, corticosterone,
oxytocin, renin, and prolactin. 5-HT2 receptor agonists, in
addition to precursors of 5-HT and 5-HT releasing agents,
produce head twitching in mice, and wet-dog shakes and
back muscle contractions in rats. Truly selective agonists
have not been described, since aMe-5-HT, DOI, DOM and
DOB all recognise other receptors of the 5-HT2 receptor
class. The production of drug discriminative stimulus prop-
erties to 5-HT2 receptor agonists, e.g. (-)2,5,-dimethoxy-4-
methamphetamine (DOM) can be blocked by 5-HT2 receptor
antagonists such as ketanserin. LSD and other hallucinogens
most probably produce hallucinations via 5-HT2A receptors.
Although their selectivity vis a vis 5-HT2B and 5-HT2C




Ketanserin and MDL 100907 are selective antagonists.
Ketanserin was developed for the treatment of hypertension,
but 5-HT2A receptor antagonism as a valid anti-hypertensive
principle is not questioned, since ketanserin is a potent α1
adrenoceptor antagonist. 5-HT2A receptor antagonists such as
risperidone, ritanserin, seroquel, olanzapine or MDL 100907
have been indicated/developed for the treatment of schizo-
phrenia. However, development of MDL 100907 for acute
schizophrenia was stopped. The combination of dopamine D2
and 5-HT2A receptor antagonism may still explain the anti-





The 5-HT2B receptor mediates fundic smooth muscle contrac-
tion. It was difficult to characterise pharmacologically, due
to operational features similar to those of other members of
the 5-HT2 family (Humphrey et al. 1993). Eventually, the
cloning of the rat, mouse and human ‘fundic’ receptors (also
known as 5-HT2F) clarified the issue. It is located on human
chromosome 2q36.3-2q37.1. 5-HT2B receptor mRNA is
found in rat fundus, gut, heart, kidney, lung and brain.
Centrally, 5-HT2B receptor-like immunoreactivity is restricted
to cerebellum, lateral septum, hypothalamus and medial
amygdala. Application of BW 723C86 into the medial
amygdala produces anxiolytic properties in rat social inter-
actions. 5-HT2B receptor activation has been implicated in
mediating hyperphagia. 5-HT2B, but not 5-HT2C, receptor
mRNA is found in a number of blood vessels. 5-HT2B recep-
tors on endothelial cells of pig pulmonary arteries and in rat
jugular vein mediate vasorelaxation via NO release. 5-HT2B
receptors contract longitudinal muscle in human small
intestine and when expressed in mouse fibroblast cells, cause
mitogenesis linked to tumour transforming activity, via MAP
kinase activation.
SB 204741 was the first selective 5-HT2B receptor antag-
onist. SB 200646 and SB 206553 have been reported as
selective 5-HT2C/2B receptor antagonists, with low affinity for
5-HT2A and other sites. BW 723C86 has agonist selectivity
at the rat 5-HT2B receptor, although less marked at human
receptors. 5-HT2B receptor antagonists such as SB 200646
may be indicated for the treatment of migraine prophylaxis,
given the vasodilatatory role of this receptor and that a
number of ‘older’ antimigraine drugs share 5-HT2B receptor
antagonism. Activation of the 5-HT2B receptor is most
probably responsible for the valvulopathies reported for





The 5-HT2C receptor was mapped to human chromosome
Xq24. Given its similar pharmacological and transductional
features with the 5-HT2A receptor, the sequence of the latter
was established by homology cloning based on the 5-HT2C
sequence. However, due to the lack of truly selective 5-HT2C
receptor ligands, our current knowledge concerning a func-























) Ketanserin (8.5-9.5) SB 200646 (7.5)†† Mesulergine (9.1) granisetron (10) GR 113808 (9-9.5)
MDL 100907 (9.4) SB 204741 (7.8) SB 242084 (9.0) ondansetron (8-10) SB 204070 (10.8)
RS 102221 (8.4) tropisetron (10-11) RS 100235 (11.2)
Radioligands [125I]DOI [3H]5-HT [125I]LSD [3H](S)-zacopride [125I]SB 207710
[3H]Ketanserin [3H]Mesulergine [3H]tropisetron [3H]GR 113808
[3H]MDL 100907 [3H]granisetron [3H]RS 57639
[3H]GR 65630
[3H]LY 278584








Gene/Chromosomal HTR2A/13q14-q21 HTR2B/2q36.3-q37.1 HTR2C/Xq24 HTR3/11q23.1-q23.2 HTR4/5q31-33
   localisation
Structural information h471 P28223 h481 P41595 h458 P28335 Multi-subunit¥ h387 Y09756AS





r471 P14842 r479 P30994 r460 P08909 5-ht
3C
r387 U20906AS
†Also activates the 5-HT2C receptor. 
††Nonselective blockade. *Multiple isoforms of the 5-HT2C receptor are produced by RNA editting.  
§The 5-HT3 receptor is a
transmitter-gated cation channel that exists as a pentamer of 4TM subunits.  ¥Human, rat, mouse, guinea-pig and ferret homologues of the 5-HT3A receptor have
been cloned that exhibit interspecies variation in pahrmacology.  A second 5-HT3 receptor subunit, 5-HT3B, imparts distinctive biophysical properties upon hetero-
oligomeric (5-HT3A/5-HT3B) versus homo-oligomeric (5-HT3A) recombinant receptors.
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tional role of this receptor is still rather limited. Thus far, its
distribution has been limited to the CNS and choroid plexus,
where the receptor was originally identified. 5-HT2C re-
ceptors in the choroid plexus couple to PLC activity, but
additional functional correlates remain largely to be found.
At least fourteen functional 5-HT2C receptor isoforms are
produced by adenine deaminase editing of the receptor
mRNA.
MK 212 and Ro 600175 are moderately selective 5-HT2C
agonists; amongst the antagonists, LY 53857, ZM 170809,
ritanserin, mianserin and mesulergine have been utilised, but
are essentially non-selective. The anxiogenic component of
mCPP may be mediated by 5-HT2C receptor activation, and
selective 5-HT2C receptor antagonists such as SB 242084
display anxiolytic properties in various animal models.
However, additional studies utilising selective agonists are
required (e.g. Ro 600175). mCPP or Ro 600175 cause
additional behavioural responses attributed to central 5-HT2C
receptor activation, e.g. hypoactivity, hypophagia, increased
penile grooming/erections and oral dyskinesia. 5-HT2C
receptor activation produces a tonic, inhibitory influence
upon frontocortical dopaminergic and adrenergic, but not
serotonergic transmission and, in part, to play a role in
neuroendocrine function. RS 102221 increased food-intake
and weight gain in rats, but failed to reverse the mCPP
induced hypolocomotion, possibly due to restricted brain
penetration. 5-HT2C receptor KO mice have spontaneous
convulsions, cognitive impairment, increased food intake and
obesity, but similar effects are not reproduced by selective
antagonists, suggesting that these changes may result in part
from neuroadaptation. Nevertheless, the 5-HT2C receptor is
an attractive target for the discovery of novel treatment for
feeding disorders.
5-HT3 receptors
5-HT3 receptors (M receptors of Gaddum and Picarelli 1957)
belong to the ligand-gated ion channel receptor superfamily,
similar to the nicotinic acetylcholine or GABAA receptors
and share electrophysiological and structural patterns. The
receptors are found on central and peripheral neurones,
where they trigger rapid depolarisation due to the opening of
non-selective cation channels (Na+, Ca++ influx, K+ efflux).
The response desensitises and resensitises rapidly. The native
5-HT3 receptor, as revealed by electron microscopy in
neuroblastoma-glioma cells, is a pentamer.
A cDNA encoding a single subunit of the 5-HT3A receptor
was isolated from a neuronally derived cell line. The human
homologue maps to chromosome 11q23.1-q23.2. Two splice
variants were reported in neuroblastoma-glioma cells (NCB-
20, NG 108-15) and rat native tissue, with similar distribu-
tion, pharmacological profiles and electrophysiological
characteristics when expressed as homomers. 5-HT3 recep-
tors are present in the CA1 pyramidal cell layer in the
hippocampus, the dorsal motor nucleus of the solitary tract
and the area postrema. In the periphery, they are located on
pre- and postganglionic autonomic neurones and on neurones
of the sensory nervous system. 5-HT3 receptor activation has
pronounced effects on the cardiovascular system and regu-
lates both motility and intestinal secretion throughout the
entire G.I. tract. Species differences provide the basis of the
pharmacological heterogeneity reported thus far. But, after
extensive investigation, a second subunit, 5-HT3B, was
cloned. The heteromeric combination of 5-HT3A and 5-HT3B
subunits provides the full functional features of the 5-HT3
receptor; since the 5-HT3A subunit alone results in receptors
with very low conductance and response amplitude, whereas
5-HT3B homomers have no activity. The patent literature has
recently reported the cloning of a third subunit, 5-ht3C, but no
details are presently available on its features. The 5-HT3
receptor, like other members of the ligand-gated ion channel
receptor superfamily, possesses additional, pharmaco-
logically distinct, recognition sites, subject to allosterical
modulation.
5-HT3 antagonists ondansetron, granisetron and tropi-
setron are used clinically in chemotherapy- and radiotherapy-
induced nausea and vomiting. Since 5-HT3 receptor acti-
vation in the brain leads to dopamine release, and 5-HT3
receptor antagonists produce central effects comparable to
those of anti-psychotics and anxiolytics; schizophrenia and
anxiety were considered as potential indications. 5-HT3
receptor antagonists have been reported to induce cognition
enhancing effects. However, there are not enough clinical
data to substantiate such activities. Similarly, that 5-HT3
antagonists should prove useful in the treatment of migraine
did not materialise in clinical studies. More recently, alo-
setron was developed for the treatment of women suffering
from IBS with diarrhoea, had to be withdrawn due to safety
reasons, but has been accepted again by the FDA with some
label restrictions.
5-HT4 receptors
5-HT4, 5-ht6 and 5-HT7 receptors all couple preferentially to
Gs and promote cAMP formation, yet they are classified as
distinct receptor classes because of their limited (< 35 %)
overall sequence identities. This subdivision is arbitrary and
may be subject to future modification.
The 5-HT4 receptor had been well described in both
central and peripheral tissues long before cloning, although
confusion between 5-HT3 and 5-HT4 receptors occurred at
times. Their existence was reported in rat neonatal colliculi
over 20 years ago, but they were not properly identified at the
time: the 5-HT4 receptor was really charaterised by Bockaert
and colleagues using substituted benzamide derivatives like
cisapride, renzapride or zacopride, acted as agonists at the
'atypical' 5-HT receptor in mouse colliculi stimulation cAMP.
Interestingly, the potent 5-HT3 receptor antagonist tropisetron
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(ICS 205-930) was described as the first competitive 5-HT4
receptor antagonist. The human 5-HT4 receptor was mapped
to chromosome 5q31-33. At least seven C-terminal splice
variants of the receptor have been identified (5-HT4a-5-HT4h),
in addition to a novel splice variant, 5-HT4hb, with a 14 amino
acid insertion in the second extracellular loop.
The 5-HT4 receptor variants couple positively to adenylyl
cyclase and share pharmacological profiles. One important
feature of the receptor is the level of constitutive activity,
which is expressed at rather low receptor levels, which may
well explain differences observed with respect to variable
intrinsic activity of a number of ligands, depending on tissue
and/or species. The pattern of expression of the human 5-HT4
receptor isoforms is tissue specific. The h5-HT4d receptor
isoform has not yet been described in other species. It is
limited to the gut, whereas the other isoforms are more
widely expressed. In addition to adenylate cyclase stim-
ulation, direct coupling to potassium channels and voltage-
sensitive calcium channel have been proposed.
The receptor is labelled with [3H]GR 113808, [3H]RS
57639 and [125I]SB 207710. In the brain, the distribution of
radioligand binding sites and mRNA is similar. RT-PCR
studies have also demonstrated 5-HT4 receptor mRNA is
present in vascular smooth muscle, confirming functional
studies. 5-HT4 receptor activation triggers acetylcholine
release in the guinea-pig ileum and contracts the oesophagus
and colon. The 5-HT4 receptor stimulates secretory responses
to 5-HT in intestinal mucosa. Electrogenic ion transport is
stimulated through 5-HT4 receptors in the small intestine;
whilst in piglet heart the receptors mediate tachycardia (right
atria) and positive inotropic effects (left atria). Similarly,
isolated human atrial appendages respond with increased
contractile force to 5-HT4 receptor agonists. 5-HT4 receptors
in the CNS appear to modulate neurotransmitter (acetyl-
choline, dopamine, serotonin and GABA) release, enhance
synaptic transmission and may play a role in memory en-
hancement; confirmation by clinical studies is lacking
though. Desensitisation is seen in many experimental in vitro
models, though readily reversible upon agonist removal in
G.I. tract preparations.
Potent and selective 5-HT4 receptor ligands are available,
e.g. the agonists BIMU 8, RS 67506 and ML 10302, and the
antagonists GR 113808, SB 204070, SB 203186, RS 23597-
190 and RS 39604; which should allow definition of the
(patho)physiological role of this receptor. Selective 5-HT4
receptor ligands may have therapeutic utility in a number of
disorders, including cardiac arrhythmia, neurodegenerative
diseases and urinary incontinence. Cisapride, a gastro-
prokinetic agent, acts as an agonist at the 5-HT4 receptor.
Tegaserod (HTF-919, Zelmac/Zelnorm), a new generation 5-
HT4 receptor partial agonist, is used to treat constipation
predominant IBS, and its therapeutic activity in functional
motility disorders of the upper G.I. tract is currently under
clinical investigation.
5-ht5 receptors
Two subtypes of the 5-ht5 receptor (5-ht5A and 5-ht5B), sharing
70 % overall sequence identity, have been found in rodents,
whereas the 5-ht5A subtype found in humans, was mapped to
chromosome 7q36.1. The human 5-ht5B receptor gene does
not encode a functional protein, due to the presence of stop
codons in its coding sequence. Human recombinant 5-ht5A
receptors inhibit forskolin stimulated cAMP production,
although the receptor may also couple positively to cAMP.
In Xenopus oocytes, the human 5-ht5A receptor couples to the
inwardly rectifying K+ channel, GIRK1.














Selective agonists - - - -
Selective antagonists (pK
B
) - - Ro 630563 (7.9) SB 258719 (7.9)
SB 271046 (7.8) SB 269970 (9.0)
SB 357134 (8.5)
Radioligands [125I]LSD [125I]LSD [125I]SB 258585 [125I]LSD
[3H]5-CT [3H]5-CT [125I]LSD [3H]SB 269970
[3H]5-HT [3H]5-CT
[3H]5-HT






Gene/Chromosomal localisation HTR5A/7q36.1 htr5b/2q11-q13 HTR6/1p35-36 HTR7/10q23.3-24.3
Structural information h357 P47898 m370 P31387 h440 P50406 h445 P34969AS
m357 P30966 r370 P35365 m440 NP_067333 m448 P32304
r357 P35364 r438 P31388 r448 P32305AS
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Diversity of serotonin receptors
5-ht5 mRNA is present in hypothalamus, hippocampus,
corpus callosum, fimbria, cerebral ventricles and glia, and a
role has been sugested in reatcive gliosis. A physiological
functional response or specific 5-ht5 binding are still missing.
5-ht6 receptors
The rat 5-ht6 receptor has 438 amino acids and is positively
coupled to adenylyl cyclase via Gs. The human gene has 89
% sequence homology with its rat equivalent, and maps
chromosome region 1p35-p36. Rat and human 5-ht6 receptor
mRNA is located in the striatum, amygdala, nucleus ac-
cumbens, hippocampus, cortex and olfactory tubercle, but
has not been found in peripheral organs. Circumstantial
evidence suggests the 5-ht6 receptor to be expressed endog-
enously in neuronal tissue.
The 5-ht6 receptor promotes accumulation of cAMP.
NCB 20 and N18TG2 cells and rat striatal neuronal cultures
express a receptor which couples positively to adenylyl
cyclase and displays an operational profile consistent with the
recombinant 5-ht6 receptor. Similar evidence for the putative
5-ht6 receptor has been obtained in homogenates of pig
caudate nucleus: cAMP accumulation had a 5-ht6 receptor
profile and was antagonised by clozapine and methiothepin.
[3H]clozapine binds with nanomolar affinity to two distinct
sites in rat brain; one site displays the operational 5-ht6
receptor profile.
SB 271046 is a potent, selective, and bioavailable 5-ht6
receptor antagonist; EMDT is a selective 5-ht6 receptor
agonist. The 5-ht6 receptor is labelled with [125I]SB 258585.
Intracerebroventricular injections of 5-ht6 receptor antisense
oligonucleotides gave rise to a specific behavioural syndrome
of yawning, stretching and chewing and caused a 30 % re-
duction in the number of [3H]LSD binding sites (measured
in the presence of 300 nM spiperone). The antisense-induced
behavioural syndrome can be dose-dependently antagonised
by atropine, implying a modulatory role for 5-ht6 receptors
on cholinergic neurones. The selective 5-ht6 receptor antago-
nist, Ro 04-6790, produces a behavioural syndrome involving
an increase in acetylcholine neurotransmis-sion. Enhanced
retention of spatial learning following both antisense oligo-
nucleotides and Ro 04-6790 have been reported. A role for
the 5-ht6 receptor in the control of central cholinergic func-
tion, and thus a putative target for cognitive dysfunction such
as Alzheimer’s disease is thus suggested. In addition, anti-
sense oligonucleotide treatment reduced both food consump-
tion and body weight; the later effect was also seen following
Ro 04-6790 suggesting potential in feeding disorders.
Antipsychotics (clozapine, olanzapine, fluperlapine and
seroquel) and antidepressants (clomipramine, amitryptyline,
doxepin and nortryptyline) are 5-ht6 receptor antagonists, in
addition to multiple other affinities. This attribute tempted
speculation of an involvement of the 5-ht6 receptor in psychi-
atric disorders.
5-HT7 receptors
The 5-HT7 receptor gene is located on human chromosome
10q23.3-q24.4. It has 445 amino acids and positively mod-
ulates cAMP formation via GS. The receptor shares a low
homology with other members of the 5-HT receptor family
(< 50 %). The receptor also activates the mitogen-activated
protein kinase, ERK, in primary neuronal cultures. The
cDNA encoding the receptor contains two introns; one
located in the second intracellular loop, the other in the
predicted intracellular carboxyl terminal. Alternate splicing
of this latter intron has been reported to generate four 5-HT7
receptor isoforms (5-HT7a-5-HT7d), which differ in their C-
termini. The various isoforms have similar pharmacology,
signal transduction and to a lesser extent tissue distribution.
The 5-HT7 receptor has high affinity for the prototypical 5-
HT1 agonists 5-CT, 5-MeOT and 8-OH-DPAT, the 5HT2
receptor ligand LSD and the antagonists, ritanserin, meter-
goline, methysergide and mesulergine. It has an extensive
vascular distribution, and is responsible for the prominent,
persistent vasodilator response to 5-HT in anaesthetised
animals, and is also expressed in non-vascular smooth muscle
and the CNS.
[3H]5-CT, in the presence of (-)-cyanopindolol and
sumatriptan, labels 5-HT7 recognition sites in guinea pig
cerebral cortex membranes. Autoradiographic analysis
revealed binding sites in the medial thalamic nuclei and
related limbic and cortical regions of the guinea pig brain,
with lower densities in the sensory relay nuclei, substantia
nigra, hypothalamus, central grey and dorsal raphé nuclei, in
agreement with 5-HT7 receptor mRNA. In rat suprachias-
matic (SCN) neurones, a gamma-aminobutyric acid activated
current (IGABA) is inhibited by 5-HT, consistent with the
presence of 5-HT7 receptors in the SCN. Moreover, the
cellular localisation of rat hypothalamic 5-HT7 receptors was
suggested to be postsynaptic, with respect to serotonergic
neurones, and regulated by altered synaptic levels of endog-
enous neurotransmitter.
The presence of 5-HT7 sites in the limbic system and
thalamocortical regions, suggest a role in the affective
disorders; indeed, atypical antipsychotics, e.g. clozapine,
risperidone and antidepressants have high affinity for the 5-
HT7 receptor. 5-HT7 receptor down-regulation occurs after
chronic antidepressant treatment, and acute, but not chronic,
stress regulates 5-HT7 receptor mRNA expression.
The antagonists SB 258719 and SB 269970 are selective.
A role for the 5-HT7 receptor has been proposed in the 5-CT-
induced hypothermia in guinea pigs which is blocked by both
SB 269970 and the non-selective 5-HT7 receptor antagonist,
metergoline. SB 269970 significantly reduced time spent in
paradoxical sleep in rats. [3H]SB 269970 is a selective
radioligand for 5-HT7 receptors. The 5-HT7 receptor is the
orphan known as the ‘5-HT1-like’ receptor mediating relax-
ation of the guinea pig isolated ileum and cat saphenous vein
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and subsequently shown to mediate elevation of cAMP and
relaxation in neonatal porcine vena cava.
Putative orphan 5-HT receptors
Several endogenous 5-HT receptors have been defined
phamacologically, although a corresponding gene product
encoding the receptor has yet to be identified. As long as their
structure is unknown, these receptors are regarded as orphans
in the current nomenclature. One of these however, the so-
called ‘5-HT1-like’ receptor mediating direct vasorelaxation
corresponds to the 5-HT7 receptor (see above). On the other
hand, the situation with the remaining orphan receptors (see
Hoyer et al. 1994) has not evolved further and thus the status
quo ante remains. In particular, no progress has been made
with the 5-HT1P receptor, which is present in the gut and
whose pharmacology is reminiscent of the 5-HT4 receptors,
with the restriction that some of the ligands described, like
the 5-HT dipeptides, do not affect 5-HT4 receptors. Also, a
high affinity binding site for [3H]5-HT with novel ‘5-HT1-
like’ pharmacology has been reported in mammalian brain,
but has yet to be sufficiently characterised for inclusion in the
5-HT1 receptor family.
Conclusion
Whether the almost endless diversity in 5-HT receptors and
transporters fulfils specific physiological and/or pathophysio-
logical roles is an open question. However, it may soon be
possible to determine which form of a given receptor is
expressed in a given tissue. This will then assist in designing
drugs with an adequate profile at the target organ, assuming
it is known. The diversity in receptors described here sug-
gests that under physiological and more so under pathologi-
cal conditions, the status of the receptors may vary dramati-
cally from one subject to another, explaining differences in
responder rates to a given treatment. It is clear that receptor
cross-talk will considerably affect the responsiveness of one
patient versus another. Indeed, vascular reactivity towards
triptans varies significantly between patients possibly be-
cause of such possibilities. Depending on the nature of the
receptor isoforms (5-HT4, 5-HT7 or 5-HT2C) expressed in the
G.I. tract/vessel/brain, it could be anticipated that certain
patients may demonstrate enhanced responsivity to particular
treatments, i.e. titration may represent a rule, rather than an
exception. The human genome being almost completely
sequenced, we will know soon whether there are more 5-HT
receptors. However, given the interactions with accessory
proteins, in addition to homo- and heterodimerisation, one












































LY 53857: Ergoline-8-carboxylic acid, 6-methyl-1-(1-































RS 23597-190: Benzoic acid, 4-amino-5-chloro-2-
methoxy-, 3-(1-piperidinyl)propyl ester,
monohydrochloride
RS 39604: Methanesulfonamide, N-[2-[4-[3-[4-amino-5-
chloro-2-[(3,5-dimethoxyphenyl)methoxy]phenyl]-3-
oxopropyl]-1-piperidinyl]ethyl]-, monohydrochloride
RS 57639: 4-amino-5-chloro-2-methoxy benzoic acid 1-
(3-[2,3-dihydrobenzo[1,4]dioxin-6yl)-propyl]-
piperidin-4yl methyl ester







RU 24969: 1H-Indole, 5-methoxy-3-(1,2,3,6-tetrahydro-4-
pyridinyl)-butanedioate
SB 200646: N-(1-methyl-5-indonyl)-N’-(3-pyridyl) urea
hydrochloride



































SDZ 21009: 1H-Indole-2-carboxylic acid, 4-[3-[(1,1-
dimethylethyl)amino]-2-hydroxypropoxy]-, 1-
methylethyl ester




U 92016A: 3H-benz[e]indole-2-carbonitrile, 8-
(dipropylamino)-6,7,8,9-tetrahydro-,
monohydrochloride





ZM 170809: 2-Propanamine, N,N,2-trimethyl-1-[(3-
phenyl-2-quinolinyl)thio]-monohydrochloride
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